To build on the momentum in MASH, we—at Madrigal Pharmaceuticals and the industry more widely—must further expand approaches to diagnosis, monitoring and individualized treatment to help more patients.
To build on the momentum in MASH, we—at Madrigal Pharmaceuticals and the industry more widely—must further expand approaches to diagnosis, monitoring and individualized treatment to help more patients.